吡柔比星
注射用盐酸吡柔比星（英文缩写THP）是1979年由日本微生物化学研究所梅泽滨夫（H.Umezawa）等人研制开发的新一代蒽环类广谱抗肿瘤抗生素，获日本化合物专利，1993年经中国卫生部批准，由深圳万乐公司从日本美露香株式会社正式引进在国内进行生产、销售。经过大量的国内权威医疗机构临床验证，证明THP与同类其它蒽环类药物多柔比星(ADM)及表阿霉素(EPI)相比，对多数肿瘤（实体瘤、血液肿瘤）疗效相当;但同等情况下,THP的心脏毒性、脱发及消化道反应相对更轻，显著提高了临床用药的安全性。
主要特点是：1.抗癌谱广，抗癌活性高；2.对部分耐阿霉素的肿瘤细胞仍有效。3.能快速进入肿瘤细胞内，而在正常组织中浓度相对较低。4. 最突出的特点是副作用较小，尤其是心脏毒性、脱发、消化道反应等较少较轻。
吡柔比星是《国家基本药物目录”、《国家基本医疗保险药品目录”品种，成为肿瘤治疗的一线基本用药，得到了国家卫生行政部门和临床肿瘤专家的广泛认可。
Pirarubicin
As a new kind of anthracene nucleus broad-spectrum antitumor antibiotic, pirarubicin hydrochloride for injection (THP), is developed and explored by H. Umezawa of Micro-biochemistry Research Center of Japan in 1979. It was applied for compounds patent of Japan and was formally initiated from Mercian
Business Corp. , producing and marketing by Shenzhen Main Luck Pharmaceuticals Inc. With the approval of Ministry of Public Health of China since 1993, it is proved that comparing with other congener marcellomycin, such as Doxorubicin (ADM) or Epirubicin(EPI), THP has the same effect to major of the cancers(solid tumor or neoplastic hematologic disorder). However, under the same conditions, THP has fewer side effects such as cardiac toxicity, calvities or digestive canal reaction, and sublimates the safety of clinical medication markedly.
Chief feature: 1. It has wide anticancer spectra and high anticancer activity; 2.It is also effective to some tumor cells growing fast to ADM; 3. It can enter tumor cells quickly but has low density in normal tissue; 4. The most outstanding feature of THP is that it has very low side effect, especially the cardiac toxicity, calvities or digestive canal reactions. Pirarubicin is a breed of “Catalogue of National Essential Drugs”and “Catalogue of National Essential Medical Insurance Drugs”. It becomes the lot basic medication of tumor therapy and has been also generally accredited by National Medical Administrative Command and clinical specialists of tumors.